One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Accesshttps://doi.org/10.2139/ssrn.4106843
Copy DOI Journal: SSRN |  Publication Date: Jan 1, 2022 |
Affiliation: Chinese Academy of Medical Sciences & Peking Union Medical College, Linzhou Cancer Hospital, Harbin Medical University, Zhejiang University, Wenzhou Medical University, Dalian University, Chongqing Cancer Hospital, Chongqing University, Sichuan University, Handan College, Army Medical University, Fuyang City People's Hospital, Sichuan Cancer Hospital, Xingtai University, Xinjiang Medical University, Peking University, Zhejiang Cancer Hospital, Central South University, Shanxi Medical University, Xuzhou Medical College, Shandong First Medical University, Zhengzhou University, Henan Provincial People's Hospital, Nanjing Medical University, Hubei University of Arts and Science, Shantou University, Henan University of Science and Technology, Tianjin Medical University, Anhui Medical University, Liaoning Cancer Hospital & Institute, China Medical University, Bengbu Medical College, Tongji University, University of Science and Technology of China, Anhui Provincial Hospital, University of Chinese Academy of Sciences, Liuzhou General Hospital, Chongqing Medical University, Hubei Cancer Hospital, Guangdong Medical College, Henan UniversityEfficacy and Safety of Rezivertinib (BPI-7711) in Patients with Locally Advanced or Metastatic/Recurrent <i>EGFR</i> T790M Mutated NSCLC: A Phase IIb Study
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
